Chimin(SH:603222) Xin Lang Cai Jing·2025-11-11 02:16Core Points - Jimin Health's stock price increased by 2.08% on November 11, reaching 10.33 CNY per share, with a market capitalization of 5.424 billion CNY [1] - The company has seen a year-to-date stock price increase of 52.14%, with a recent 5-day increase of 3.20% and a 60-day increase of 45.90% [1] - Jimin Health has appeared on the trading leaderboard 13 times this year, with the latest occurrence on September 11, where it recorded a net purchase of 66.0795 million CNY [1][2] Financial Performance - For the period from January to September 2025, Jimin Health reported a revenue of 545 million CNY, a year-on-year decrease of 20.21%, and a net profit of -77.1504 million CNY, a decrease of 371.51% [2] - The company has distributed a total of 127 million CNY in dividends since its A-share listing, with 10.7447 million CNY distributed in the last three years [3] Shareholder Information - As of September 30, Jimin Health had 58,100 shareholders, an increase of 107% from the previous period, with an average of 9,035 circulating shares per shareholder, a decrease of 51.69% [2] Business Overview - Jimin Health, established on December 24, 1996, and listed on February 17, 2015, is primarily engaged in the research, production, and sales of medical devices, medical services, and large-volume intravenous products [1] - The company's revenue composition includes 52.07% from pharmaceutical manufacturing, 46.01% from medical services, 1.54% from pharmaceutical trading, and 0.38% from other sources [1] Industry Classification - Jimin Health is classified under the pharmaceutical and biological industry, specifically in medical devices and consumables, with involvement in innovative drugs, cell therapy, in vitro diagnostics, antigen testing, and medical devices [2]